Human ENO3 activation kit by CRISPRa

CAT#: GA101408

ENO3 CRISPRa kit - CRISPR gene activation of human enolase 3



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
ENO3 rabbit polyclonal antibody
    • 25 ul

CNY 800.00
CNY 1,280.00


ENO3 (Myc-DDK-tagged)-Human enolase 3 (beta, muscle) (ENO3), transcript variant 2
    • 10 ug

CNY 3,656.00
CNY 3,990.00


ENO3 Rabbit monoclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol ENO3
Locus ID 2027
Kit Components

GA101408G1, ENO3 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA101408G2, ENO3 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA101408G3, ENO3 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001193503, NM_001976, NM_053013
Synonyms GSD13; MSE
Summary This gene encodes one of the three enolase isoenzymes found in mammals. This isoenzyme is found in skeletal muscle cells in the adult where it may play a role in muscle development and regeneration. A switch from alpha enolase to beta enolase occurs in muscle tissue during development in rodents. Mutations in this gene have be associated glycogen storage disease. Alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Jul 2010]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...